CDK3/CCNE2(CDK3/cyclin E2)
Sign in to save this workspaceUniProt CDK3: Q00526; cyclin E2: O96020 · PDB · AlphaFold (Q00526), AlphaFold (O96020) · Substrate: RB Protein · Clone: full length / full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Defactinib | 92.0% | 8.0% | 92.68 | 0.450 |
| 2 | Abemaciclib | 62.1% | 37.9% | 91.48 | 0.563 |
| 3 | Pralsetinib | 58.7% | 41.3% | 93.43 | 0.643 |
| 4 | Vemurafenib | 33.0% | 67.0% | 96.49 | 0.598 |
| 5 | Pacritinib | 29.0% | 71.0% | 88.64 | 0.452 |
| 6 | Darovasertib | 23.2% | 76.8% | 96.99 | 0.719 |
| 7 | Ponatinib | 21.0% | 79.0% | 78.23 | 0.534 |
| 8 | Neratinib | 19.8% | 80.2% | 93.18 | 0.597 |
| 9 | Repotrectinib | 19.7% | 80.3% | 84.21 | 0.608 |
| 10 | Alectinib | 17.3% | 82.7% | 95.49 | 0.651 |
| 11 | Lapatinib | 16.3% | 83.7% | 99.25 | 0.616 |
| 12 | Regorafenib | 16.2% | 83.8% | 95.99 | 0.719 |
| 13 | Ruxolitinib | 16.2% | 83.8% | 98.25 | 0.592 |
| 14 | Midostaurin | 15.8% | 84.2% | 78.64 | 0.500 |
| 15 | Pexidartinib | 14.6% | 85.4% | 99.49 | 0.631 |
| 16 | Afatinib | 13.4% | 86.6% | 98.50 | 0.709 |
| 17 | Entrectinib | 12.4% | 87.6% | 93.69 | 0.671 |
| 18 | Alpelisib | 12.2% | 87.8% | 97.22 | 0.720 |
| 19 | Nilotinib | 11.6% | 88.4% | 96.49 | 0.765 |
| 20 | Dabrafenib | 11.3% | 88.7% | 94.74 | 0.633 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on CDK3/CCNE2
Each point is one of the 92 approved drugs; color = inhibition % on CDK3/CCNE2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…